KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginFCF Payout RatioGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Regeneron Pharmaceuticals (REGN) EBITDA Margin (2016 - 2025)

Regeneron Pharmaceuticals has reported EBITDA Margin over the past 17 years, most recently at 21.96% for Q4 2025.

  • Quarterly results put EBITDA Margin at 21.96% for Q4 2025, down 46.0% from a year ago — trailing twelve months through Dec 2025 was 32.0% (up 42.0% YoY), and the annual figure for FY2025 was 32.0%, up 42.0%.
  • EBITDA Margin for Q4 2025 was 21.96% at Regeneron Pharmaceuticals, down from 39.33% in the prior quarter.
  • Over the last five years, EBITDA Margin for REGN hit a ceiling of 1897.54% in Q4 2022 and a floor of 21.96% in Q4 2025.
  • Median EBITDA Margin over the past 5 years was 38.91% (2025), compared with a mean of 299.24%.
  • Biggest five-year swings in EBITDA Margin: soared 178038bps in 2021 and later plummeted -186098bps in 2023.
  • Regeneron Pharmaceuticals' EBITDA Margin stood at 1827.75% in 2021, then increased by 4bps to 1897.54% in 2022, then plummeted by -98bps to 36.56% in 2023, then plummeted by -39bps to 22.42% in 2024, then decreased by -2bps to 21.96% in 2025.
  • The last three reported values for EBITDA Margin were 21.96% (Q4 2025), 39.33% (Q3 2025), and 38.5% (Q2 2025) per Business Quant data.